BMJ Open

The geko™ device is now available through the NHS Supply Chain

Retrieved on: 
Mercoledì, Maggio 1, 2024
Leg, Supply, Pain, Patient, Knee, Cancer, BMJ Open, NHS, Acceleration, Calf, DOI, Hope, National Health Service, Hospital, Skin, PMID, SOC, Recurrence, Common fibular nerve, Carbon, INT, IWJ, Quality-adjusted life year, Mouth ulcer, Nursing, Health, Cardiovascular disease, Standard of care, Wound healing, RCT, Life imprisonment, Quality of life, Anxiety

HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain. The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.

Key Points: 
  • HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain .
  • The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.
  • "We're delighted to be listed on the NHS Supply Chain," said Bernard Ross, CEO and Founder of Sky Medical Technology.
  • Now with this wider access, through the NHS Supply Chain, geko device ease of ordering will further help NHS wound care nurses reduce the time managing wounds."

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Retrieved on: 
Lunedì, Marzo 18, 2024
CCL7, COVID, Major, BMJ Open, IL-6, AKI, Inflammation, Lung, Biomarker, Hospital, Acute respiratory distress syndrome, TMX Group, CXCL10, Acute kidney injury, SARS-CoV-2, Human, TSX, Chemokine, Arch, Cytokine, Periodic breathing, Phase, OTCQB, CXCL8, Liver, Somayaji, BMJ, Randomness, Pharmaceutical industry

New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.

Key Points: 
  • New biomarker data from the pandemic Phase II trial, provides further scientific rationale for Arch to bring LSALT peptide into larger trials to inhibit DPEP-1 mediated organ inflammation.
  • Arch is currently performing a Phase II human trial to support LSALT peptide as a first ever treatment for preventing cardiac surgery-associated acute kidney injury.
  • The results of the Phase II trial provided first-ever evidence validating DPEP-1 as a mediator of organ inflammation and therapeutic target in humans.
  • The new data provides more scientific rationale for Arch to advance LSALT peptide to prevent leukocyte recruitment and organ inflammation for other indications, including a larger Phase II trial targeting cardiac surgery-associated AKI, which recently began recruiting patients.

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Retrieved on: 
Martedì, Febbraio 13, 2024
Urinary tract infection, Gastroesophageal reflux disease, Research, Heartburn, Toxicity, Magnesium, Polyp, Liver, CYP, CGA, Achlorhydria, Esophagitis, Patient, PBM, Vitamin B12, Vonoprazan, Kidney, Spine, Lactation, Absorption, Hypokalemia, SCAR, Calcium, Express Scripts, TIN, Endoscopy, Tablet, Express, Magnesium deficiency, Hypocalcemia, Diarrhea, Hypersensitivity, Physician, Gastritis, Malabsorption, GERD, PPI, Hypertension, SJS, Enzyme inhibitor, EGFR, Stevens–Johnson syndrome, Indigestion, Nelfinavir, Clostridioides, Abdominal pain, Hip, Pharmacy, Enzyme, Glomus tumor, FDA, CDAD, Atazanavir, Risk, BMJ Open, Wrist, Drug, Impairment, Pharmaceutical industry

Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.

Key Points: 
  • Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.
  • doi:10.1136/ bmjgast-2022-000941
    VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated:
    for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.
  • Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR

Global HIV Progress Overstated: AHF Calls for UNAIDS Audit

Retrieved on: 
Lunedì, Gennaio 8, 2024
Public Policy, Healthcare Reform, Social Activism, Pharmaceutical, Communications, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, LGBTQ+, Foundation, Science, AIDS, Consumer, Research, Health, BMJ, HIV/AIDS, Death, AHF, WHO, Disease, Medical journal, UNAIDS, Poverty, Infection, World Health Organization, HIV, BMJ Open, Patient, AIDS Healthcare Foundation, Pharmaceutical industry

Inflated numbers would mean that the progress against the epidemic has been slower than anticipated, and a greater investment of resources will be needed to put the global HIV response back on track.

Key Points: 
  • Inflated numbers would mean that the progress against the epidemic has been slower than anticipated, and a greater investment of resources will be needed to put the global HIV response back on track.
  • “We have offered to assist UNAIDS with the auditing process in anyway practical.”
    The following is a full text of the open letter:
    We write this letter to express our alarm over the inaccuracy of global HIV treatment statistics being reported by UNAIDS.
  • We urge UNAIDS and the WHO to audit at least 10% of patient charts across the globe.
  • We believe that our proposal will be an exciting new chapter for global AIDS that will yield gratifying results.

ivWatch Technology Demonstrates High Sensitivity in Wilhelmina Children's Hospital Study

Retrieved on: 
Martedì, Luglio 11, 2023
IV, NICU, QI, PDSA, Blood, Incidence, Journal, Patient, McMaster University Medical Centre, Quality, Observation, JVA, Hospital, Claude Pivi, BMJ Open, Medical device, Risk management, Medical imaging, NEWS

NEWPORT NEWS, Va., July 11, 2023 /PRNewswire/ -- A new study published in The Journal of Vascular Access (JVA) examines several important metrics that describe the performance of the ivWatch patient monitoring system for infiltrations and extravasations in a 24-bed neonatal intensive care unit (NICU) at Wilhelmina Children's Hospital, part of the University Medical Centre of Utrecht in the Netherlands. The continuous IV monitoring system was deployed to identify the leakage of infused fluids via short peripheral IV catheters (PIVC), which are commonplace with neonatal patients and are placed more than 200 times monthly in this NICU. This condition is referred to as peripheral IV infiltration/extravasation (PIVIE).

Key Points: 
  • During the monitoring time of the study with ivWatch technology, 11 infiltrations were detected in 21 monitored PIVCs, which corresponds to a 52.4% infiltration incidence rate.
  • The study was conducted using the PDSA (plan, do, study, act) model of quality improvement (QI) to provide a systematic framework for identifying PIVIE risks and evaluating the ivWatch model 400's continuous monitoring of PIVCs.
  • The ivWatch system has been clinically tested in laboratory and real-world settings, demonstrating high sensitivity and specificity across various patient populations.
  • The study concluded: "Continuous infusion site monitoring using the ivWatch [system] suggests this technology offers the potential to detect PIVIE events earlier than relying on intermittent observation alone (i.e.

TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing

Retrieved on: 
Giovedì, Luglio 6, 2023
MIC, National Transportation Safety Board, Frontiers, HLA, CSO, Immune tolerance, Clinical trial, Antibody, DSA, Fungal infection, Transplant, Incidence, EUR, Patient, Immune system, Series, Autoimmune disease, Methylprednisolone, Kidney transplantation, University Hospital Heidelberg, Leukapheresis, BMJ Open, Autoimmunity, Dentistry, Medical device, Immunology

Furthermore, the company is publishing 5-year follow-up data of a Phase I trial of its MIC-Lx cell therapy.

Key Points: 
  • Furthermore, the company is publishing 5-year follow-up data of a Phase I trial of its MIC-Lx cell therapy.
  • Our preclinical studies also demonstrate great potential in autoimmune disease"
    On the back of these promising results, TolerogenixX also reported a EUR 7 million second closing of its Series A financing round now totaling EUR 11.6 million.
  • "We are very pleased that we were able to add EUR 7 million to our Series A financing round," Schaier said.
  • "In the current financing environment, this is a further validation of our approach, enabling us to successfully complete our Phase II program."

Pregnant this winter? Here's how to prepare for COVID and get vaccinated

Retrieved on: 
Sabato, Aprile 15, 2023
Vaccine, Infection, Department, Cold medicine, Pregnancy, Placenta, Life, Sepsis, Vaccination, Parent, Breast milk, COVID-19, Service, Immunity, Department of Health and Aged Care, Woman, Research, COVID, Cell, Antibody, Messenger, Ventilation, Death, Risk, Place of birth, Time, Doherty Institute, Fertility, Preterm birth, Miscarriage, Stillbirth, BMJ, Ageing, BMJ Open, Safety, Virus, Pfizer, Disease, Pharmaceutical industry, Birth control

Most pregnant women are aware of the recommendations around getting vaccinated against influenza (flu) and pertussis (whooping cough).

Key Points: 
  • Most pregnant women are aware of the recommendations around getting vaccinated against influenza (flu) and pertussis (whooping cough).
  • However, COVID is still relatively new, meaning women who have never been pregnant before may be unaware of the current recommendations and research.

1 in 10 pregnant women are vaccine hesitant

    • We are following more than 6,000 Australian women in the Birth in the Time of COVID-19 study who were pregnant or gave birth during the first two years of the pandemic.
    • We also sent them follow-up surveys at two months, six months, 12 months and 24 months after giving birth.
    • Our latest findings reporting on 2,144 responses to questions on vaccine uptake, published in the journal BMJ Open show around one in ten pregnant women and just over one in 13 postnatal women were hesitant to get a COVID vaccination.

So what does the evidence say?

    • But real-life data shows no evidence of a negative impact on fertility, miscarriage, stillbirth, preterm birth or other problematic pregnancy outcomes, and no negative impact on newborns or via breastfeeding.
    • We also know most side effects are mild and go away within a couple of days.
    • The baby may have a higher risk of premature birth (before 37 weeks of pregnancy), stillbirth or admission to the hospital newborn unit.

What do pregnant women need to know now winter is coming?

    • If you are trying to become pregnant, you do not need to delay vaccination or avoid becoming pregnant after vaccination.
    • For pregnant women, there are special considerations that need to be discussed so informed decisions can be made.
    • Advice from the Department of Health and Aged Care is that if you are pregnant, you should have two COVID vaccine doses (called the primary course).

What if you’re already vaccinated?

    • Recommendations for booster doses if you are pregnant are now the same as for non-pregnant people of the same age.
    • To book a COVID vaccine or booster dose, use the health Service Finder or text “Hey Eva” a callback service for Easy Vaccine Access.

LiverMultiScan Shown to Be a Cost-Effective Alternative to Liver Biopsies for Monitoring Patients with Autoimmune Hepatitis

Retrieved on: 
Mercoledì, Settembre 21, 2022
Managed Care, Hospitals, Health, Medical Devices, Chronic liver disease, BMJ Open, Health, Precision medicine, Safety, NHS, 5-1-1, Oxford University Hospitals NHS Foundation Trust, Doctor of Philosophy, Autoimmune hepatitis, Woman, Magnetic resonance, McKay, Liver disease, MRI, Incidence, Patient, Genetics, Cancer, Physician, Technology, Systematic review, Fatty liver disease, Liver, Viral hepatitis, Diagnosis, Meta-analysis, AIH, Research, Hepatitis, Immune system, Innovation, Live Damage, Master of Science, Conditional sentence, Digestive Diseases and Sciences, Medical imaging, MBBS

Noninvasive imaging with LiverMultiScan can detect the presence and extent of liver fibro-inflammation in a risk-free manner, resulting in reduced liver biopsy frequency for AIH patients, noted Mamta Bajre, MBBS, M.Sc.

Key Points: 
  • Noninvasive imaging with LiverMultiScan can detect the presence and extent of liver fibro-inflammation in a risk-free manner, resulting in reduced liver biopsy frequency for AIH patients, noted Mamta Bajre, MBBS, M.Sc.
  • By eliminating risks and complications associated with liver biopsy, LiverMultiScan helps improve patient outcomes and experience.
  • Although necessary for diagnosis, liver biopsy is not sustainable for long-term monitoring of patients with AIH.
  • LiverMultiScan is a novel technology that addresses a critical unmet need for noninvasive techniques to diagnose and monitor patients with chronic liver diseases such as nonalcoholic steatohepatitis, autoimmune hepatitis, or viral hepatitis.

CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

Retrieved on: 
Giovedì, Agosto 4, 2022
Biotechnology, General Health, Other Health, Health, Health Technology, Heart transplantation, Precision medicine, Lung transplantation, Unintentional discharge, Acquisition, Annual report, PLOS, Medication, FACS, Integration, Patient, Bertram Cohler, College, Communication, Surgery, Nasdaq, Liver transplantation, The Journal of Heart and Lung Transplantation, Journal, Research, BCPS, Tampa General Hospital, BMJ Open, Health, Kidney transplantation, Behavioral medicine, Doctor of Pharmacy, Tom Hucker, Immunosuppression, CEO, Medicine, Smartphone, National Kidney and Transplant Institute, Caregiver, Systematic review, Transplant, SEC, Awareness, Medical device, Dentistry, Heart, MD

MedActionPlan PRO is a medication management and adherence platform designed to simplify post-transplant medication regimens.

Key Points: 
  • MedActionPlan PRO is a medication management and adherence platform designed to simplify post-transplant medication regimens.
  • By integrating MedActionPlan PRO into the AlloCare app, participating transplant centers can now push personalized education, medication regimen details, and reminder alerts directly to their patients smartphone.
  • CareDxs strategy of delivering patient-centered digital health solutions to improve the transplant journey has come to fruition with the seamless integration of MedActionPlan PRO with our AlloCare app, said Reg Seeto, CEO and President of CareDx.
  • We are incredibly proud to expand the medication management features on our AlloCare app to help thousands of patients and their clinicians work together to successfully manage complex medication regimens for optimal transplant health and longevity.

Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Retrieved on: 
Mercoledì, Agosto 3, 2022
FDA, Health, Clinical Trials, Research, Pharmaceutical, Science, IL-6, Hospital, Autoimmunity, Mouse, COVID-19, Inflammation, TNF, MS, Annual report, The Journals of Gerontology, Life, Pathology, Epilepsy, Cox, Disability, Degenerative disease, Frailty, Company, Chronic pain, MPH, CNS, Nasdaq, Biomarker, Ageing, FDA, Maintenance, BioMaPS Institute for Quantitative Biology, Disease, Metformin, Journal, Thyroiditis, Risk, BMJ Open, Pharmacokinetics, Vivo, Forward-looking statement, Longevity, Tumor necrosis factor, Genta (company), Serum, Intention, CMO, Sex, Death, Central nervous system, Multiple sclerosis, Immune system, Warfarin necrosis, Cytokine, Johns Hopkins School of Medicine, Traffic barrier, Cannabidiol, Sarcopenia, Pharmaceutical industry, Vaccine, CBD, MD

View the full release here: https://www.businesswire.com/news/home/20220803005056/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220803005056/en/
    We are very excited that this important early data with our lead product MYMD-1 has been published in a prestigious medical journal, said Chris Chapman, MD, President, Director, and CMO of MyMD Pharmaceuticals.
  • Our ongoing Phase 2 study of MYMD-1 in sarcopenia/frailty, a result of a pathological aging process, is going well.
  • The companys scientific advisory board met recently and agreed to move to the next higher dose in the study.
  • In vivo, a longitudinal cohort of C57BL/6 mice, was randomized to receive either MYMD-1, high-dose rapamycin, or low-dose rapamycin plus metformin.